TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17982319

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg (plus orphenadrin 30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: paracetamol 1 g
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg
Number of subjects: 40
Study: 15179792

Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 90
Study: 11749745

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 236

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Blinding index
Number of subjects: 236
Study: 9848296

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) pretreatment for 14 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no OC pretreatment)
Number of subjects: 83
Study: 7926350

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 32
Study: 2679269

Group type: EXPERIMENTAL
Intervention: Standardized verbal instruction alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standardized verbal instruction plus an automatic visual signal during inspiration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both treatment protocols
Number of subjects: 100
Study: 388168

Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study: 30709384

Group type: EXPERIMENTAL
Intervention: Psychosocial support services
Number of subjects: 349
Study: 28182535

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic analysis of treatment groups
Number of subjects: 0
Study: 26540907

Group type: EXPERIMENTAL
Intervention: Positive expiratory vibrating device
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional method (control group)
Number of subjects: 39
Study: 23627345

Group type: EXPERIMENTAL
Intervention: Active mononuclear cell depletion by leukapheresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham leukapheresis
Number of subjects: 30
Study: 21801977

Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Office Mercury Sphygmomanometer
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 24-hour Ambulatory Blood Pressure Monitor (ABPM)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Daytime Ambulatory Blood Pressure Monitor (ABPM)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Home Self-Measurement
Number of subjects: 101

Group type: COMPARATOR
Intervention: Comparison of office methods vs ambulatory methods
Number of subjects: 101

Group type: COMPARATOR
Intervention: Achievement of therapeutic goals
Number of subjects: 101
Study: 19255407

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg IV once every 4 weeks plus GA 20 mg subcutaneously once daily for ≤ 20 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Natalizumab + GA
Number of subjects: 110
Study: 18575843

Group type: EXPERIMENTAL
Intervention: SmartCare/PS
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SmartCare/PS (adjusted)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 15196161

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, lidocaine and epinephrine mixture (5-FU + LE)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (serum saline injection)
Number of subjects: 76
Study: 11772799

Group type: EXPERIMENTAL
Intervention: Cisapride 0.3 mg/kg orally 1 h before surgery and placebo 6 h later (Group C1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cisapride before and after surgery (Group C2)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 96
Study: 9763159

Group type: EXPERIMENTAL
Intervention: Adolescent smoking (defined as smoking before age 18)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Adolescent smoking
Number of subjects: 1042
Study: 8087821

Group type: EXPERIMENTAL
Intervention: 10 mg TNTG applied for 16 h with a 'nitrate‐free' interval of 8 h
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 10 mg TNTG applied for 16 h followed by a 'nitrate‐low' interval of 5 mg applied for 8 h
Number of subjects: 129
Study: 2587133

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (10 mg intramuscularly, repeated if delivery did not occur in 4 days, followed by 20 mg orally daily until the end of the 34th week if pregnancy continued)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 98
Study: 782504

Group type: EXPERIMENTAL
Intervention: 1% Ciclopirox solution
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 15208931

Group type: EXPERIMENTAL
Intervention: E + AA + PA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E + PA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D + PA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D + AA + PA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D + AA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E + AA
Number of subjects: 60
Study: 30477705

Group type: EXPERIMENTAL
Intervention: Exercise Program (EP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fitness Trackers (FT)
Number of subjects: 60
Study: 29127060

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: G-CSF (lenograstim) 15 μg/kg for 5 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: G-CSF for 5 days followed by leukapheresis and intravenous infusion of CD133-positive stem cells (0.2 × 10^6 cells per kg per infusion)
Number of subjects: 81
Study: 26456672

Group type: EXPERIMENTAL
Intervention: Isosorbid mononitrate 20 mg tablet once daily applied vaginally until delivery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo vaginal tablets
Number of subjects: 300
Study: 23583234

Group type: EXPERIMENTAL
Intervention: 2000 IU/day of alpha-tocopherol
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 20 mg/day memantine
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 2000 IU/day alpha-tocopherol plus 20 mg/day memantine
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 22360820

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg (RSV40)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg (RSV20)
Number of subjects: 825

Group type: COMPARATOR
Intervention: atorvastatin 80 mg (ATV80)
Number of subjects: 825
Study: 20820832

Group type: EXPERIMENTAL
Intervention: TMC207 (novel agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 0
Study: 17588187

Group type: EXPERIMENTAL
Intervention: AT nerve block with LA (Bupivacaine, 2.5 mg/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IA injection with LA (Bupivacaine, 2.5 mg/ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo injection (isotonic saline)
Number of subjects: 28
Study: 16307966

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 100
Study: 12212873

Group type: EXPERIMENTAL
Intervention: Computerized injection device (Wand)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional anesthetic delivery system
Number of subjects: 40
Study: 9466020

Group type: COMPARATOR
Intervention: Standard heparin and protamine management (Group 1)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Heparin and protamine by in vitro titration (Group 2)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Heparin dose titrated (Group 3)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Protamine dose titrated (Group 4)
Number of subjects: 135
Study: 9097747

Group type: EXPERIMENTAL
Intervention: Patients with TIA and abnormal iris transluminance
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy subjects without transluminance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with TIA with positive iris transluminance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with TIA with abnormal iris transluminance
Number of subjects: 46
Study: 2497830

Group type: EXPERIMENTAL
Intervention: Booklet given to patients at discharge (65 patients)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (66 patients)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Booklet group (65 patients)
Number of subjects: 131
Study: 777074

Group type: EXPERIMENTAL
Intervention: 0.22 mg of tartrazine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 31866161

Group type: EXPERIMENTAL
Intervention: Kinesio Taping® Group (n=21)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo Group (normal surgical tape) (n=21)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-treatment control Group (n=21)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study: 30683591

Group type: EXPERIMENTAL
Intervention: Letrozole and Clomiphene Citrate (CC) - 2.5 mg letrozole and 50 mg CC daily on cycle days 3–7 for one treatment cycle
Number of subjects: 70

Group type: COMPARATOR
Intervention: Letrozole alone - 2.5 mg letrozole daily on cycle days 3–7 for one treatment cycle
Number of subjects: 70
Study: 28267466

Group type: EXPERIMENTAL
Intervention: 12-week multi-domain physical rehabilitation intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 360
Study: 27143274

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <140 mm Hg)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target SBP <180 mm Hg)
Number of subjects: 2839
Study: 24411490

Group type: EXPERIMENTAL
Intervention: Bofutsushosan with probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bofutsushosan with placebo
Number of subjects: 0
Study: 22259078

Group type: EXPERIMENTAL
Intervention: Blue light exposure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Red light exposure
Number of subjects: 10
Study: 19370427

Group type: EXPERIMENTAL
Intervention: Daily pretreatment megavoltage computed tomography (MVCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Simulated bone alignment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily MVCT
Number of subjects: 10
Study: 17184429

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol anesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sevoflurane-fentanyl anesthesia
Number of subjects: 39
Study: 14607494

Group type: EXPERIMENTAL
Intervention: RANKL protein levels in peri-implant tissues of patients with implant failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPG protein levels in peri-implant tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RANK mRNA expression in cells containing wear particles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RANKL mRNA expression in peri-implant tissues
Number of subjects: 0
Study: 11303975

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate 900 mg/day
Number of subjects: 388

Group type: COMPARATOR
Intervention: Gabexate mesilate 1,500 mg/day
Number of subjects: 388
Study: 9130904

Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 100
Study: 8195331

Group type: EXPERIMENTAL
Intervention: Follicular fluid (20% v/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progesterone (1 mmol/l)
Number of subjects: 0
Study: 3539980

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nalmefene administration
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal weight control subjects
Number of subjects: 7
Study: 29625873

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of the lower uterine segment (LUS) thickness with a threshold value of 3.5mm.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice without ultrasound measurement of LUS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of the lower uterine segment (LUS) thickness.
Number of subjects: 0
Study: 28442422

Group type: EXPERIMENTAL
Intervention: 1Hz rTMS of the left TPJ
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1Hz rTMS of the bilateral TPJ
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 26450586

Group type: EXPERIMENTAL
Intervention: REFOCUS intervention, which includes recovery-promoting relationships and working practices, specific details on dosage and duration not available.
Number of subjects: 0
Study: 23995537

Group type: EXPERIMENTAL
Intervention: MHC1-MB (molecular beacon targeting myosin heavy chain 6/7 mRNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MHC1-MB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MB-based purified cardiomyocytes
Number of subjects: 0
Study: 21495077

Group type: EXPERIMENTAL
Intervention: Nursing guideline intervention (increased individualized pleasant activities and decreased unpleasant events)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Nursing guideline intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study: 18451674

Group type: EXPERIMENTAL
Intervention: Increasing Kt/V to 1.40 in the HEMO study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kt/V >1.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment time (t) in NCDS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose targeting observational studies (OS)
Number of subjects: 0
Study: 16221942

Group type: EXPERIMENTAL
Intervention: KnowledgeLink (infobutton application linked to Micromedex)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: KnowledgeLink (infobutton application linked to SkolarMD)
Number of subjects: 359
Study: 14732787

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (SWT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 6-Minute Walking Test (6MWT)
Number of subjects: 18
Study: 11088036

Group type: EXPERIMENTAL
Intervention: Teicoplanin (15 mg/kg single dose)
Number of subjects: 3027

Group type: COMPARATOR
Intervention: Cefazolin (2 g initial dose, followed by 1 g every 8 hours for 6 doses over 2 days)
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 3027

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 3027
Study: 9161110

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric methods for sample size calculations and analysis
Number of subjects: 0
Study: 8270290

Group type: EXPERIMENTAL
Intervention: Kamalahar 500 mg three times a day for 15 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Kamalahar 500 mg
Number of subjects: 52
Study: 3304401

Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: mefenamic acid
Number of subjects: 35
Study: 29024542

Group type: EXPERIMENTAL
Intervention: Momelotinib tablet, 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Momelotinib tablet with low-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Momelotinib tablet with high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Momelotinib tablet with omeprazole
Number of subjects: 0
Study: 27552173

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 24847894

Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sodium hypochlorite
Number of subjects: 113
Study: 22079088

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 or 100 mg
Number of subjects: 98
Study: 18973957

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 98
Study: 18296124

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (n=84)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (n=77)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Donepezil (n=84)
Number of subjects: 168
Study: 16152825

Group type: EXPERIMENTAL
Intervention: kurarinone combined with interferon alpha-1b (IFNalpha-1b)
Number of subjects: 146

Group type: COMPARATOR
Intervention: interferon alpha-1b (IFNalpha-1b)
Number of subjects: 146

Group type: COMPARATOR
Intervention: kurarinone (KR)
Number of subjects: 146

Group type: COMPARATOR
Intervention: none (Control Group D)
Number of subjects: 146
Study: 11343248

Group type: EXPERIMENTAL
Intervention: CDCA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DCA
Number of subjects: 10
Study: 9832099

Group type: EXPERIMENTAL
Intervention: Color kinesis imaging in the TOF group
Number of subjects: 19
Study: 8137492

Group type: EXPERIMENTAL
Intervention: FARM (epirubicin hydrochloride)
Number of subjects: 77

Group type: COMPARATOR
Intervention: ADR (doxorubicin hydrochloride)
Number of subjects: 77
Study: 2781858

Group type: EXPERIMENTAL
Intervention: Combined rabies vaccine with aluminium hydroxide-adsorbed tetanus toxoid on days 0 and 21
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-1-1 regimen of PVRV alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aluminium-free tetanus toxoid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined rabies vaccine with aluminium hydroxide-adsorbed tetanus toxoid
Number of subjects: 0
Study: 1109698

Group type: EXPERIMENTAL
Intervention: Eyes covered in the recovery room only (Group 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Eyes uncovered (Control Group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Eyes covered in the operating room and recovery room (Group 1)
Number of subjects: 150
Study: 7358496

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31398573

Group type: EXPERIMENTAL
Intervention: Delayed oxytocin (DO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Immediate oxytocin (IO)
Number of subjects: 64
Study: 29191231

Group type: EXPERIMENTAL
Intervention: Multiple imputation analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counting all participants' LTFU as non-users of contraception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete case analysis
Number of subjects: 0
Study: 27927658

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (Hb ≤100 g/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (Hb ≤80 g/L)
Number of subjects: 0
Study: 24438370

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA) 20 mg/Conjugated Estrogens (CE) 0.45 or 0.625 mg
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Conjugated Estrogens (CE) 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Bazedoxifene (BZA) 20 mg
Number of subjects: 1843
Study: 22020758

Group type: EXPERIMENTAL
Intervention: Family-based intervention (16 cognitive-behavioral, small-group sessions)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 339
Study: 19729593

Group type: EXPERIMENTAL
Intervention: IABP support 1:2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IABP support 1:1
Number of subjects: 25
Study: 17632131

Group type: EXPERIMENTAL
Intervention: 60 mg trospium chloride once daily
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study: 15334434

Group type: EXPERIMENTAL
Intervention: Mutual support groups
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mutual support groups (for those attending at least 5 of 10 sessions)
Number of subjects: 112
Study: 11751144

Group type: EXPERIMENTAL
Intervention: BMS 284756 (600 mg single dose)
Number of subjects: 8
Study: 9526970

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8011237

Group type: EXPERIMENTAL
Intervention: Subcutaneous rIL‐2 (0.2 x 10(6), 0.7 x 10(6), or 2 x 10(6) units/m2 per day for 5 consecutive days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous rIL‐2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous rIL‐2 (highest dose)
Number of subjects: 16
Study: 2544152

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin-DHE (LMWH-DHE)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional heparin-DHE (heparin-DHE/A)
Number of subjects: 191
Study: 1201808

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHA) and lawsone (2-hydroxy-1,4-naphthoquinone)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dihydroxyacetone (DHA) alone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHA)
Number of subjects: 5
Study: 31431236

Group type: EXPERIMENTAL
Intervention: Home-based training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Home-based training and Supervised training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 65
Study: 28736006

Group type: EXPERIMENTAL
Intervention: TIVA+EA
Number of subjects: 66

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 66
Study: 25938807

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 240